ArticleDermatology and therapy2026
Summary of Research: Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
of the original article "Immunogenicity of Dupilumab in Adult and Pediatric Patients with Atopic Dermatitis." Dupilumab is a monoclonal antibody used to treat atopic dermatitis (AD) in patients 6 months and older. Antibody drugs can induce immunogenicity by activating patient's immune system to produce antidrug antibodies (ADAs). Some ADAs may impact drug's activity ("neutralizing antibodies" [NAbs]) and/or safety. In this study, we evaluated anti-dupilumab ADAs in patients with AD from seven randomized controlled trials (N = 2992) and two open-label extensions (OLEs; N = 2287). The highest proportion of patients with ADAs in any study was 9%, 16%, 5%, and 2% in adults, adolescents, children, and infants, respectively. In any trial, fewer than 1% of patients had high-titer ADAs and up to 5% had NAbs. With longer observation in OLEs, most high or moderate ADA titers decreased over time while patients continued dupilumab treatment. Except in some rare cases of high-titer ADAs, the pharmacokinetics, efficacy, and safety of dupilumab were similar between ADA-positive and ADA-negative patients. One patient with high-titer ADAs developed serum sickness and discontinued dupilumab. In conclusion, most dupilumab-treated patients across age groups did not develop ADAs. Most ADA-positive patients had low-titer, NAb-negative ADAs. Most ADA-positive patients benefited from continuing dupilumab treatment [1] (Fig. 1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.